ストックスクリーナーアプリを入手
6.14
1.44%
-0.09
前日終値:
$6.23
開ける：
$6.27
24時間の取引高:
7,620
Relative Volume:
0.20
時価総額：
$27.69M
収益：
$85.53M
当期純損益:
$-9.78M
株価収益率:
-2.797
EPS:
-2.1952
ネットキャッシュフロー:
$1.28M
1週間 パフォーマンス:
-0.16%
1か月 パフォーマンス:
-0.97%
6か月 パフォーマンス:
-2.60%
1年 パフォーマンス:
+33.62%
1日の値動き範囲:
$6.105
$6.36
1週間の範囲:
$6.07
$6.72
52週間の値動き範囲:
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
名前
Harvard Bioscience Inc
セクター
電話
(508) 893-8999
住所
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, MDLN, ALC, RMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
6.14 | 27.69M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
406.78 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
151.94 | 41.87B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
41.04 | 34.70B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.81 | 33.07B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
203.87 | 29.57B | 5.54B | 1.52B | 1.74B | 10.37 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-09 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | 開始されました | Northland Capital | Outperform |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | ダウングレード | Janney | Buy → Neutral |
| 2018-01-24 | 繰り返されました | Janney | Buy |
| 2018-01-23 | 繰り返されました | The Benchmark Company | Buy |
| 2016-11-17 | 開始されました | Singular Research | Buy |
| 2015-07-28 | 開始されました | The Benchmark Company | Buy |
すべてを表示
Harvard Bioscience Inc (HBIO) 最新ニュース
Harvard Bioscience focuses on life science instruments as investors weigh long-term demand - ad-hoc-news.de
Harvard Bioscience | SD: Specialized disclosure report - Moomoo
HBIO Stock Price, Quote & Chart - ChartMill
Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO) - TradingView
HBIO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Price to earnings forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Price to book forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Enterprise value to EBITDA forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Harvard Bioscience Inc (HBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harvard Bioscience Inc (HBIO) Institutional Confidence - TradingKey
Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harvard Bioscience (HBIO) Slips Slightly, Holding Above Support at $5.71Quality Factor - dars.gov.et
Harvard Bioscience holds key trading range, shares between support and resistance - AD HOC NEWS
HBIO News | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill
Harvard Bioscience Inc (HBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harvard Bioscience Inc (HBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Harvard Bioscience Inc (HBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harvard Bioscience Inc (HBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Director at Harvard Bioscience (HBIO) granted 16,556 restricted stock units - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 restricted stock units - Stock Titan
Harvard Bioscience (NASDAQ: HBIO) awards director 16,556 RSUs - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 RSUs in new grant - Stock Titan
Director at Harvard Bioscience (HBIO) awarded 16,556 RSUs - Stock Titan
Harvard Bioscience | 8-K: Harvard Bioscience Announces First Quarter 2026 Financial Results - Moomoo
Harvard Bioscience Shareholders Expand Equity Plans, Elect Directors - TipRanks
Harvard Bioscience (NASDAQ: HBIO) shareholders approve equity and ESPP share increases - Stock Titan
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 - MSN
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
HBIOHarvard Bioscience Inc Website Traffic and Mobile Apps Usage - Finviz
Harvard Bioscience: HBIO stock stalls, margin pressure in focus - Bez Kabli
HBIO PE Ratio & Valuation, Is HBIO Overvalued - Intellectia AI
HBIO Q1 2026 Earnings: EPS Surprises to the Upside Despite Challenging QuarterEstimate Dispersion - thelegaladvocate.com
Harvard Bioscience Slips as Traders Assess Support Levels; HBIO Down Nearly 3%Open Trading Community - Newser
Harvard Bioscience (HBIO) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.33Real Trader Insights - Newser
Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story - AD HOC NEWS
Harvard Bioscience, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-05-15 - Seeking Alpha
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts - Investing.com UK
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts By Investing.com - Investing.com Australia
Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake - Stock Titan
Harvard Bioscience Transitions to Translational Science Focus in 2026 - HarianBasis.co
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New Product Innovations - GuruFocus
Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss By Investing.com - Investing.com Nigeria
Harvard Bioscience Q1 2026 Earnings Call Transcript - MarketBeat
HBIO Maintains Positive Outlook for FY26 Financial Performance - GuruFocus
Harvard Bioscience (HBIO) Reports Q1 Earnings and Reaffirms 2026 Revenue Guidance - GuruFocus
Discontinued operations of Harvard Bioscience, Inc. – FWB:HBI0 - TradingView
Harvard Bioscience Reaffirms Full-Year 2026 Financial Guidance >HBIO - Moomoo
Harvard Bioscience Inc (HBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.71%
0.45%
大文字化:
|
ボリューム (24 時間):